RestructuringMay 13, 2026, 04:27 PM
MDxHealth Exits Resolve UTI Business; Sets 2026 Core Revenue Guidance $110-115M
AI Summary
MDxHealth reported Q1 2026 results, with revenue up 13% to $27.4 million and a net loss of $8.9 million. The company announced a strategic decision to discontinue its Resolve UTI offering and laboratory operations in Plano, Texas, citing an increasingly uncertain reimbursement landscape and a recent Medicare policy reversal. This proactive exit allows MDxHealth to focus on its core prostate cancer precision diagnostics business, for which it set updated 2026 revenue guidance of $110-115 million, representing 20-26% year-over-year growth. The company also initiated an AI-dedicated strategic initiative to enhance operations and clinical value, despite facing a $10.4 million Medicare recoupment decision for Resolve mdx claims.
Key Highlights
- MDxHealth to discontinue Resolve UTI business and Plano, Texas lab operations due to reimbursement uncertainty.
- Updated 2026 core cancer business revenue guidance set at $110-115 million, representing 20-26% YoY growth.
- Q1 2026 revenue increased 13% to $27.4 million compared to prior year period.
- Q1 2026 net loss was $8.9 million, a 4% decrease from $9.2 million in prior year period.
- Q1 2026 Adjusted EBITDA was ($4.3) million, a 226% increase in loss compared to ($1.3) million YoY.
- Cash and cash equivalents stood at $43.2 million as of March 31, 2026.
- Received $10.4 million Medicare recoupment decision for historical Resolve mdx claims, which the company is contesting.
- Paid $15.0 million 2025 earnout to Exact Sciences on April 15, 2026.